Tag Archives: Promedior

Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More

Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention. It’s still unclear whether the cases are tied to legally sold products or devices modified by e-cigarette users, but the CDC this week identified a “potential toxin of concern”—Vitamin E […]

East Coast Biotech Roundup: X4, Rgenix, Alnylam, Intellia & More

What summer doldrums? It’s still not even Labor Day, yet the deals are already coming fast and furious. So fire up the grill and read on for some Series A rounds, crossover investments, data readouts, option-to-buy deals and more. —As Xconomy reported this week, a stealthy Cambridge, MA-based startup called X4 Pharmaceuticals raised a $37.5 […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories | Tagged ALN-PCS, Alnylam Pharmaceuticals, Amgen, Amicus Therapeutics, aprepitant, Ariad Pharmaceuticals, Baxalta, Bristol-myers Squibb, Cholesterol, Columbia University, CRISPR-Cas9, deals, Emend, epidermolysis bullosa, Essential Tremor, Fibrosis, Gene editing, Genzyme, google, Henri Termeer, Intellia Therapeutics, Intercept Pharmaceuticals, Ivenix, Jeff Jonas, John Crowley, John Maraganore, Joslin Diabetes Center, Life Sciences, Masoud Tavazoie, Memorial Sloan-Kettering Cancer Center, Merck, Mozobil, obeticholic acid, Paula Ragan, PCSK9, plerixafor, Primary Biliary Cirrhosis, priority review voucher, Promedior, Regeneron Pharmaceuticals, Rgenix, RNAi, Rockefeller University, rolapitant, Roundups, Sage Therapeutics, Sanofi, ScioDerm, Shahram Seyedin-Noor, startups, Suzanne Bruhn, Tesaro, Tetraphase Pharmaceuticals, The Medicines Co., Varubi, VC, WuXi Healthcare Ventures, X4 Pharmaceuticals | Comments Off

Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug

New drugs for fibrosis, an internal, often deadly type of scarring, have become the centerpiece of a number of biotech deals over the past few years. The latest just crossed the wires this morning, as Bristol-Myers Squibb has just nabbed an option to buy Promedior, of Lexington, MA. Bristol-Myers (NYSE: BMY) is paying $150 million […]

Posted in Boston, Boston blog main, National blog main, New York blog main, New York top stories, San Francisco blog main, Seattle blog main | Tagged Amira Pharmaceuticals, Biogen, Bristol-myers Squibb, CTI BioPharma, deals, Fabry Disease, Gaucher, Gilead Sciences, Idiopathic Pulmonary Fibrosis, Incyte, Intermune, Jakafi, Janus Kinase, Life Sciences, Morganthaler, myelofibrosis, Pentraxin 2, Polaris Partners, Promedior, Replagal, Roche, ruxolitinib, Shire, startups, Stromedix, Suzanne Bruhn, Transkaryotic Therapies, Vipriv | Comments Off

CTI Goes Up, And Down, And Back Up On Phase 3 Myelofibrosis News

Seattle’s CTI Biopharma (NADSAQ: CTIC) just ended a rollercoaster trading day. First thing Monday, the firm released positive Phase 3 trial results for its myelofibrosis treatment, pacritinib, and shares shot up 11 percent higher than the Friday closing price of $2.65. Before noon, shares had given back all those gains, then immediately began to rise […]

Posted in Boston blog main, National blog main, Seattle, Seattle blog main, Seattle top stories | Tagged Baxter, Biotech, Cell Therapeutics, CTI BioPharma, FDA, Gilead Sciences, Incyte, JAK inhibitors, Jakafi, Life Sciences, myelofibrosis, Novartis, Pacritinib, PERSIST-1, PERSIST-2, Pixantrone, Promedior, ruxolitinib | Comments Off

ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead

Cancer immunotherapy and gene therapy grabbed many of the headlines from this past weekend’s American Society of Hematology meeting in San Francisco, and a number of the companies those fields look primed to cash in with big offerings in the coming weeks. Two such companies are already prepping to do so: Juno Therapeutics of Seattle, […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories | Tagged Acceleron Pharma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Agios Pharmaceuticals, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, American Society of Hematology, Amgen, Bellicum Pharmaceuticals, Beta-Thalassemia, blinatumumab, Blincyto, BlueBird Bio, cancer, CAR-T, Carfilzomib, CD19, Celgene, Cellectis, clinical trials, Drugs, eculizumab, Epizyme, FDA, Foundation Medicine, Gene Therapy, hemophilia, Immunotherapy, IPO, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Kyprolis, Life Sciences, Mayo Clinic, Multiple Myeloma, myelodysplastic syndrome, myelofibrosis, Non-Hodgkin's Lymphoma, Novartis, paroxysmal nocturnal hemoglobinuria, PD-1, Pfizer, PRMT5, Promedior, RNA Interference, Soliris, sotatercept, Sunesis Pharmaceuticals, University of Pennsylvania, Vosaroxin | Comments Off

Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis?

Swiss pharmaceutical giant Roche said Sunday it would buy Intermune (NASDAQ: ITMN) of Brisbane, CA, for $8.3 billion. It’s by far the high water mark of a growing wave in recent years of deals for drugs to treat pulmonary fibrosis, a deadly scarring of the lungs that often has no known cause. The idiopathic version—meaning […]

Posted in Boston blog main, National blog main, National top stories, New York blog main, New York top stories, San Diego blog main, San Diego top stories, San Francisco, San Francisco blog main, San Francisco top stories | Tagged Acquisition, Amira Pharmaceuticals, Biogen Idec, Biotech, Bristol-myers Squibb, Celgene, Genoa Pharmaceuticals, Idiopathic Pulmonary Fibrosis, Intermune, IPF, Jilly Evans, John Hutchinson, Life Sciences, M&A, Michael Gilman, PharmAkea Therapeutics, Promedior, Pulmonary Fibrosis, Roche, Stromedix | Comments Off

Promedior Sees Hope in Small Myelofibrosis Study

[Updated 6/2/2014. See below.] Myelofibrosis, a rare and potentially fatal type of leukemia, isn’t an easy disease to treat. The only drug that’s been approved by the FDA approval to treat it, Incyte’s (NASDAQ: INCY) ruxolitinib (Jakafi), attacks the symptoms rather than the cause, and often leaves patients needing blood transfusions. Several companies are trying […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories | Tagged 15Five, Anemia, AstraZeneca, bone marrow, cancer, Cell Therapeutics, Drugs, Fabre, Gaucher, Geron, Gilead Sciences, Incyte, JAK inhibitors, Jakafi, Life Sciences, morgenthaler, myelofibrosis, Pentraxin 2, Platelets, Polaris Partners, Promedior, Replagal, ruxolitinib, Sanofi, Shire, Suzanne Bruhn, Transkaryotic Therapies, Vipriv | Comments Off

Michigan Life Sciences Roundup: Swift Biosciences, Aastrom

A few Southeast Michigan biotech companies are in the news today: —Swift Biosciences, based in Ann Arbor, has just rolled out its Accel-NGS DNA Library kit, the first in a suite of new products for next-generation sequencing sample preparation that the company plans to release in 2013. “What we have is a kit that makes […]

Posted in Detroit, Detroit blog main, National blog main | Tagged Aastrom Biosciences, Accel-NGS, Biotech, Cardiovascular Disease, Critical Limb Ischemia, Dan Orlando, Dilated Cardiomyopathy, DNA sequencing, Dominick Colangelo, Eli Lilly, Entrepreneurship, Esperion Therapeutics, Genome, innovation, Life Sciences, PCR, Promedior, startups, Steve Spotts, Swift Biosciences, Tim Mayleben | Comments Off

Promedior Joins Ranks of Woman-Helmed Biotechs in Massachusetts

It seems counterintuitive, given that only a handful of life sciences companies of any size have women at the helm, but the biotech startup world is a relatively good place to be a woman. A 2006 survey of New England biotech firms found that 21 percent were founded by women. By comparison, a nationwide study […]

Posted in Boston, Boston blog main, National blog main | Tagged Avaxia Biologics, Biotech, Drugs, Fibrosis, Lexington, Life Sciences, people, Promedior, Rare diseases, SHire Pharmaceuticals, startups, Suzanne Bruhn, Transkaryotic Therapies, women | Comments Off

Promedior, Aveo, Ra, and More Boston Life Sciences Headlines

Drugs, devices, and nonprofits showed up in this week’s New England life sciences news. —Promedior, a maker of treatments for tissue damage known as fibrosis, is moving its headquarters from Pennsylvania to Boston and has hired Suzanne Bruhn, a veteran of the Irish drug giant Shire’s Human Genetic Therapies division, as its new CEO. —Cambridge, MA-based Aveo Pharmaceuticals […]

Posted in Boston, Boston blog main, National blog main | Tagged Amyotrophic Lateral Sclerosis, Astellas Pharma, Aveo Pharmaceuticals, bayer, cancer, Clinical Trial, deals, Devices, Drugs, Financing, funding, Johnson & Johnson Development Corporation, Life Sciences, Lou Gehrig's Disease, Medtronic Corporation, Mitralign, Onyx Pharmaceuticals, Oxford Bioscience Partners, Prize4Life, Promedior, Ra Pharmaceuticals, Roundup, Shire, Suzanne Bruhn, Tivozanib, Tom Maniatis, Triathlon Medical Ventures | Comments Off← Older posts

Tag Archives: Promedior

Archives

Meta